Option chain shows key data for Panbela Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Panbela Therapeutics.

Panbela Therapeutics (OTC:PBLA) Stock, Option Chain

Panbela Therapeutics

Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.

Long Ideas

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

ALPS ETF Trusthen & Steers Global Realty Majors ETF

PBLA

SINT

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Are Preparing To Pump This Month

laboratory-563423_1920

Equities

Movers

General

Panbela Therapeutics announced acceptance of SBP-101 abstract for presentation and disclosed details of a public offering, expecting approximately $9.0 million in gross proceeds.

What&#39;s Going On With Panbela Therapeutics Stock Today?

Earnings

Eurozone

Commodities

Global

Intraday Update

BFRG

CDLX

SNCE

SOFI

U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 75 points on Monday.

The Dow traded up 0.03% to 38,121.11 while the NASDAQ rose 0.48% to 15,529.84. The S&amp;P 500 also rose, gaining, 0.19% to 4,900.27.

Crude Oil Down Over 1%; Science 37 Holdings Shares Spike Higher

PANBELA THERAPEUTICS INC by Panbela Therapeutics, Inc.

Panbela Therapeutics Inc

Press Releases

Panbela Provides Business Update and Reports Q1 2024 Financial Results

Panbela Announces Oral Presentation at Digestive Disease Week (DDW):

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

Panbela Provides Business Update and Reports Q2 2024 Financial Results

First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

Panbela Provides Business Update and Reports Q3 2024 Financial Results

Roth MKM

Maxim Group

Roth Capital

Comments

Panbela Therapeutics

Panbela Therapeutics (PBLA) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell